[HTML][HTML] A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
P Monk, E Lam, A Mortazavi, K Kendra… - Journal of …, 2014 - journals.lww.com
This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD
IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell
carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 that may be altered by
sorafenib including the percentages of natural T-regulatory cells (Tregs), myeloid-derived
suppressor cells (MDSC), and STAT5 phosphorylation (pSTAT5) in T cells were evaluated.
We hypothesized that the proposed treatment schedule is feasible and safe and may lead to …
IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell
carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 that may be altered by
sorafenib including the percentages of natural T-regulatory cells (Tregs), myeloid-derived
suppressor cells (MDSC), and STAT5 phosphorylation (pSTAT5) in T cells were evaluated.
We hypothesized that the proposed treatment schedule is feasible and safe and may lead to …